Endometriosis Market Outlook, Trends And Future Opportunities (2024-2031)

Endometriosis Market is Forecasted to Hit US$ 3.8 Bn By 2031 | CAGR 9.8%

  • Date: 12 May, 2024
  • Author(s): Sagar Karlekar

The Global Endometriosis Market is expected to reach US$ 3.8 Billion in 2031, registering a CAGR of 9.8% during the forecast period of 2024-2031. The global Endometriosis Market is a rapidly growing segment within the pharmaceutical and medical device industry, driven by the increasing prevalence of the condition and the development of innovative treatment options. Endometriosis is a chronic gynecological disorder characterized by the growth of endometrial tissue outside the uterus, leading to severe pelvic pain, infertility, and other complications. With an estimated 176 million women worldwide affected by endometriosis, there is a significant demand for effective management strategies and therapies.

The growth of the Endometriosis Market is fueled by several factors, including rising awareness about the condition, improved diagnostic techniques, and the introduction of novel therapeutic approaches. Pharmaceutical companies are actively investing in research and development efforts to bring new drugs to market, such as selective progesterone receptor modulators (SPRMs), aromatase inhibitors, and immunotherapies. Additionally, advancements in minimally invasive surgical techniques and the increasing adoption of robotic-assisted procedures are contributing to the market's growth.

The Endometriosis Market is witnessing significant growth, driven by favorable market dynamics and ample opportunities for innovation. The increasing prevalence of the condition, coupled with the growing demand for effective treatment options, has created a substantial market opportunity. Furthermore, the introduction of novel therapies and advanced diagnostic techniques is expected to drive market growth by addressing unmet clinical needs and improving patient outcomes. The market is also benefiting from increasing healthcare expenditure, favorable reimbursement policies, and the expansion of healthcare infrastructure in emerging markets.

Endometriosis is a chronic gynecological condition where the endometrium tissue, which normally lines the inside of the uterus, grows outside the uterus on other organs like the ovaries, fallopian tubes, and the tissue lining the pelvis. This misplaced tissue behaves like normal endometrium, thickening, breaking down, and bleeding with each menstrual cycle, leading to inflammation, scarring, and the formation of adhesions or ovarian cysts. Endometriosis can cause severe pelvic pain, heavy periods, infertility, and other complications.

Key Report Insights:

  • Major Market Driver: Increasing prevalence of endometriosis, affecting around 176 million women worldwide (estimates from the World Endometriosis Research Foundation).
  • Company Actions: Pharmaceutical companies are actively researching and developing new treatments for endometriosis, including novel oral medications like gonadotropin-releasing hormone (GnRH) antagonists, aromatase inhibitors, and selective progesterone receptor modulators (SPRMs). Examples include Orilissa (AbbVie), Linzagolix (ObsEva/Kissei), and Vilaprisan (Bayer).
  • Diagnostic Advancements: Improved diagnostic techniques like transvaginal ultrasound, magnetic resonance imaging (MRI), and laparoscopy have facilitated earlier detection and accurate staging of endometriosis.
  • Technological Shift: The development of non-invasive diagnostic tests, such as endometrial biomarkers or proteomics, could revolutionize the diagnosis and monitoring of endometriosis, reducing the need for invasive surgical procedures.


  • Rising Prevalence and Awareness: The increasing prevalence of endometriosis, affecting approximately 176 million women worldwide, is a significant driver for the market's growth. Additionally, initiatives by healthcare organizations and patient advocacy groups have raised awareness about the condition, leading to earlier diagnosis and treatment-seeking behavior.
  • Development of Novel Therapies: Pharmaceutical companies are actively investing in research and development efforts to introduce novel therapies for endometriosis, such as selective progesterone receptor modulators (SPRMs), aromatase inhibitors, and immunotherapies. These innovative treatments aim to provide more effective and targeted management options with fewer side effects, driving market growth.


  • Adoption of Minimally Invasive Surgical Techniques: The Endometriosis Market is witnessing a trend towards the adoption of minimally invasive surgical techniques, such as laparoscopic and robotic-assisted surgeries.
  • Integration of Digital Health Solutions: The integration of digital health solutions, including mobile applications, telehealth platforms, and wearable devices, is emerging as a significant trend in the Endometriosis Market.

Market Opportunity:

The development of non-invasive diagnostic tests presents a significant opportunity for the Endometriosis Market, enabling earlier detection and timely intervention.

Key Regional Insights:

  • North America is expected to be the largest region in the Endometriosis Market, with a market share of approximately 38%. Prominent companies such as AbbVie, Pfizer, and Myovant Sciences have a strong presence in this region. Some region-specific market drivers include advanced healthcare infrastructure, favorable reimbursement policies, and increased awareness about the condition.
  • Europe is expected to be the second-largest region in the Endometriosis Market, with a market share of around 27.5%. Companies like Bayer AG, Ferring Pharmaceuticals, and Jenapharm have a strong presence in this region. Market drivers in Europe include the availability of innovative treatment options, supportive healthcare policies, and increasing focus on women's health issues.
  • Prominent companies operating in the Endometriosis Market include AbbVie, Bayer AG, Pfizer, Myovant Sciences, ObsEva SA, Ferring Pharmaceuticals, Takeda Pharmaceutical, Astellas Pharma, Kissei Pharmaceutical, and Shionogi.

Market Segmentation:

  • By Treatment Type
    • Hormonal Therapy
    • Non-Hormonal Therapy
    • Surgical Treatment
    • Others (Pain Management, Complementary Therapies)
  • By Route of Administration
    • Oral
    • Parenteral
    • Others (Vaginal, Transdermal)
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others (Clinics, Fertility Centers)
  • By End-User
    • Hospitals
    • Gynecology Clinics
    • Fertility Centers
    • Research Institutes
    • Others (Home Care Settings)
  • By Age Group
    • Below 30 Years
    • 30-45 Years
    • Above 45 Years
  • By Severity
    • Minimal
    • Mild
    • Moderate
    • Severe
  • By Regions
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

Market Definition:

“The Endometriosis Market refers to the industry focused on developing and providing treatments, diagnostic tools, and management strategies for endometriosis, a chronic gynecological condition where the endometrium tissue grows outside the uterus. This condition affects millions of women worldwide, causing severe pelvic pain, infertility, and other complications. The Endometriosis Market encompasses various pharmaceutical and medical device companies involved in researching, developing, and commercializing hormonal therapies, non-hormonal treatments, surgical interventions, and diagnostic tools to diagnose, manage, and potentially cure endometriosis.”

Why iDataAcumen

Actionable Insights

Access to robust insights derived from our rich internal databases and external sources

Deep Industry Acumen

Our industry experts have a keen understanding of macro and micro economic trends

Research Customization

On-demand generation of research and insights tailored to your needs

Vast Industry Coverage

We provide market intelligence services across multiple healthcare domains